Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 1, 2010, Pages 27-31

  Reeves, David ^a   Liu, Chin Y ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Enoxaparin; Fondaparinux; Heparin; Prophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY MASS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBESITY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS; POLYSACCHARIDES; PRACTICE GUIDELINES AS TOPIC; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 77749304815     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209104379     Document Type: Article

References (15)

1. Geerts WH, Bergqvist D., Pineo GF, Heit JA, Samama CM, Lassen MR et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8 th edition). Chest 2008 ; 133: 381S - 453S.
2. Lyman GH, Khorana AA, Falanga A., Clarke-Pearson D., Flowers C., Jahenzeb M. et al. American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007 ; 25: 5490-5505. (Pubitemid 350232226)
3. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J. et al. NCCN clinical practice guidelines in oncology: Venous thromboembolic disease v1.2008. (Available at http://www.nccn.org/professionals/physician-gls/ PDF/vte.pdf, Accessed June 30, 2008 ).
4. Alikhan R., Cohen AT, Combe S., Samama MM, Desjardins L., Eldor A. et al. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003 ; 14: 341-346.
5. Leizorovicz A., Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004 ; 110: 874-879.
6. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomized placebo controlled trial. BMJ 2006 ; 332: 325-329.
7. Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The heparin prophylaxis study group. Lancet 1996 ; 347: 1357-1361.
8. Mismetti P., Laporte-Simitsidis S., Tardy B., Cucherat M., Buchmüller A., Juillard-Delsart D. et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomized clinical trials. Thromb Haemost 2000 ; 83: 14-19.
9. Gallus AS, Hirsh J., O'Brien SE, McBride JA, Tuttle RJ, Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976 ; 235: 1980-1982.
10. Clagett GP, Reisch JS Prevention of venous thrombembolism in general surgical patients. Ann Surg 1988 ; 208: 227-240.
11. Bergqvist D., Eldor A., Thorlacius-Ussing O., Combe S., Cossec-Vion MJ et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997 ; 84: 1099-1103.
12. Bergqvist D., Burmark US, Flordal PA, Frisell J., Hallböök T., Hedberg M. et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995 ; 82: 496-501.
13. Agnelli G., Bergqvist D., Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005 ; 92: 1212-1220.
14. Bergqvist D., Agnelli G., Cohen AT, Eldor A., Nilsson PE, Le Moigne-Amrani A. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002 ; 346: 975-980. (Pubitemid 34983247)
15. Rasmussen MS, Jorgensen LN, Wille-Jøgensen P., Nielsen JD, Horn A., Mohn AC et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study. J Thromb Haemost 2006 ; 4: 2384-2390.